Format
Sort by

Send to:

Choose Destination

Results: 4

1.

Potential benefits and limitations of utilizing chondroprogenitors in cell-based cartilage therapy.

Jayasuriya CT, Chen Q.

Connect Tissue Res. 2015 Aug;56(4):265-71. doi: 10.3109/03008207.2015.1040547.

PMID:
26075411
2.

Matrilin-3 inhibits chondrocyte hypertrophy as a bone morphogenetic protein-2 antagonist.

Yang X, Trehan SK, Guan Y, Sun C, Moore DC, Jayasuriya CT, Chen Q.

J Biol Chem. 2014 Dec 12;289(50):34768-79. doi: 10.1074/jbc.M114.583104. Epub 2014 Oct 20.

PMID:
25331953
3.

Matrilin-3 chondrodysplasia mutations cause attenuated chondrogenesis, premature hypertrophy and aberrant response to TGF-β in chondroprogenitor cells.

Jayasuriya CT, Zhou FH, Pei M, Wang Z, Lemme NJ, Haines P, Chen Q.

Int J Mol Sci. 2014 Aug 21;15(8):14555-73. doi: 10.3390/ijms150814555.

4.

Matrilin-3 induction of IL-1 receptor antagonist is required for up-regulating collagen II and aggrecan and down-regulating ADAMTS-5 gene expression.

Jayasuriya CT, Goldring MB, Terek R, Chen Q.

Arthritis Res Ther. 2012 Sep 11;14(5):R197. doi: 10.1186/ar4033.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk